Edition:
India

Pluristem Therapeutics Inc (PSTI.OQ)

PSTI.OQ on NASDAQ Stock Exchange Capital Market

1.26USD
22 Jun 2018
Change (% chg)

$0.02 (+1.61%)
Prev Close
$1.24
Open
$1.24
Day's High
$1.26
Day's Low
$1.24
Volume
7,319
Avg. Vol
70,959
52-wk High
$2.12
52-wk Low
$1.06

Select another date:

Wed, Jun 13 2018

Photo

Israel's Pluristem sees positive results from leg pain study

TEL AVIV Israel's Pluristem Therapeutics Inc, a developer of placenta-based stem cell products, said on Tuesday it had positive results from a mid-stage study of its therapy to treat leg pain known as intermittent claudication (IC).

Israel's Pluristem sees positive results from leg pain study

TEL AVIV, June 12 Israel's Pluristem Therapeutics Inc, a developer of placenta-based stem cell products, said on Tuesday it had positive results from a mid-stage study of its therapy to treat leg pain known as intermittent claudication (IC).

FDA clears Pluristem radiation treatment for emergency use

HAIFA, Israel Pluristem Therapeutics Inc, a developer of placenta-based stem cell products, said the U.S. Food and Drug Administration has cleared the emergency use of its therapy to treat acute radiation exposure in a nuclear event.

FDA clears Pluristem radiation treatment for emergency use

HAIFA, Israel, April 30 Pluristem Therapeutics Inc, a developer of placenta-based stem cell products, said the U.S. Food and Drug Administration has cleared the emergency use of its therapy to treat acute radiation exposure in a nuclear event.

BRIEF-U.S. FDA Clears Pluristem’S Phase III Study In Treatment Of Muscle Injury Following Hip Fracture Surgery

* U.S. FDA CLEARS PLURISTEM’S PHASE III STUDY IN TREATMENT OF MUSCLE INJURY FOLLOWING HIP FRACTURE SURGERY

BRIEF-Pluristem Therapeutics Says Co Sold Its Entire Holdings In CHA Biotech Co For About $10.5 Mln

* PLURISTEM THERAPEUTICS - ON JAN 8, CO SOLD ITS ENTIRE HOLDINGS IN CHA BIOTECH CO LTD, CONSISTING OF 400,368 SHARES OF CHA, FOR ABOUT $10.5 MILLION

BRIEF-FDA Clears Pluristem’s Expanded Access Program To Initiate Treatments Of Critical Limb Ischemia

* PLURISTEM THERAPEUTICS - U.S. ‍FDA CLEARED CO'S EXPANDED ACCESS PROGRAM FOR USE OF PLX-PAD CELL TREATMENT IN PATIENTS WITH CRITICAL LIMB ISCHEMIA​

Select another date: